Headlines

Legal online publication Law360 recognized medical attorney Ann E. Rice Ervin as one of five 2020 Rising Stars in the area of product liability.

A $192 million settlement was approved today to resolve shareholder claims that alleged SCANA Corp. and certain of the energy company’s executives violated the Securities Exchange Act.

Updates to the label for Elmiron®, a medication used to treat bladder pain and inflammation, now warn of potential, permanent damage to the retina that could cause irreversible vision loss.

The U.S. Food and Drug Administration sent a warning letter to Allergan, now AbbVie, reprimanding the medical device manufacturer for serious deficiencies in Allergan’s post-approval studies of its recalled breast implants, which have been linked to an increased risk of cancer.

Recent changes to New Jersey state law in May 2019 that broadened the statute of limitations, or the time in which a person can file a claim, for civil childhood sexual abuse claims are constitutional, Morris County’s Superior Court Judge Paul Bogaard ruled.

New York extended its deadline to file civil sexual abuse claims under the state’s Child Victims Act to Aug. 14, 2021 due to COVID-19.

Litigation concerning claims that the popular antacid medication Zantac causes cancer continues to move forward with U.S. District Judge Robin Rosenberg on May 8, 2020, appointing attorneys to lead the multidistrict litigation, a national consolidation of individual cases.

Thousands of women who allege Johnson & Johnson’s talc-based baby powder caused their ovarian cancer can move forward with claims against the company, a federal judge ruled on April 27.

Recalls involving the name-brand heartburn drug Zantac (ranitidine) and similar generic versions culminated April 1 in the FDA asking drug manufacturers to immediately withdraw all prescription and over-the-counter ranitidine products, including generic ones, from the U.S. market due to concerns that they may contain…

Motley Rice, as co-lead and trial counsel for end-payor plaintiffs, helped reach a $62.5 million class action settlement to resolve claims alleging pharmaceutical drug manufacturers engaged in anticompetitive conduct to delay market entry of generic Loestrin 24 FE.